Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2004-1-8
pubmed:abstractText
Advances in immunosuppressive therapy over the past decade have led to dramatic improvements in graft survival. With the development of new agents, the focus of the transplant community is to establish regimens that maintain excellent graft survival rates but with fewer toxicities including infection, nephrotoxicity, malignancy, and cosmetic effects. Examples include the use of steroid-free protocols and calcineurin avoidance regimens, which are currently being studied by NAPRTCS. The ultimate goal of transplant immunosuppressive therapy is the induction of tolerance. As we learn more about immune function from basic and clinical research, tolerance to allografts seems a more reachable goal.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Antilymphocyte Serum, http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine, http://linkedlifedata.com/resource/pubmed/chemical/Immunoconjugates, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Muromonab-CD3, http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid, http://linkedlifedata.com/resource/pubmed/chemical/Propylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus, http://linkedlifedata.com/resource/pubmed/chemical/Sphingosine, http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus, http://linkedlifedata.com/resource/pubmed/chemical/abatacept, http://linkedlifedata.com/resource/pubmed/chemical/alemtuzumab, http://linkedlifedata.com/resource/pubmed/chemical/basiliximab, http://linkedlifedata.com/resource/pubmed/chemical/daclizumab, http://linkedlifedata.com/resource/pubmed/chemical/everolimus, http://linkedlifedata.com/resource/pubmed/chemical/fingolimod, http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0031-3955
pubmed:author
pubmed:issnType
Print
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1283-300
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:14710781-Antibodies, Monoclonal, pubmed-meshheading:14710781-Antibodies, Monoclonal, Humanized, pubmed-meshheading:14710781-Antibodies, Neoplasm, pubmed-meshheading:14710781-Antilymphocyte Serum, pubmed-meshheading:14710781-Area Under Curve, pubmed-meshheading:14710781-Cyclosporine, pubmed-meshheading:14710781-Drug Therapy, Combination, pubmed-meshheading:14710781-Drug Utilization, pubmed-meshheading:14710781-Graft Survival, pubmed-meshheading:14710781-Humans, pubmed-meshheading:14710781-Immunoconjugates, pubmed-meshheading:14710781-Immunoglobulin G, pubmed-meshheading:14710781-Immunosuppressive Agents, pubmed-meshheading:14710781-Muromonab-CD3, pubmed-meshheading:14710781-Mycophenolic Acid, pubmed-meshheading:14710781-Propylene Glycols, pubmed-meshheading:14710781-Recombinant Fusion Proteins, pubmed-meshheading:14710781-Sirolimus, pubmed-meshheading:14710781-Sphingosine, pubmed-meshheading:14710781-Tacrolimus
pubmed:year
2003
pubmed:articleTitle
Current immunosuppressive agents: efficacy, side effects, and utilization.
pubmed:affiliation
Division of Nephrology, Children's Hospital and Regional Medical Center, 4800 Sand Point Way, NE 5G-1, Seattle, WA 98105-0371, USA. jodi.smith@seattlechildrens.org
pubmed:publicationType
Journal Article, Review